- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01220635
Middle School Matters Study (MSM)
February 13, 2014 updated by: Carolyn McCarty, Seattle Children's Hospital
Prevention of Depression Within Salient Adolescent Contexts
This study aims to evaluate the short-term and long-term efficacy of two preventative intervention approaches designed to support middle school youth.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study involve two parts: Part 1 entailed screening 7th and 8th graders from 4 public middle schools to identify students who may be showing moderate signs of stress.
Students who score at the designated cutoff on a depression symptoms measure received a brief check-in to determine eligibility for the follow up randomized trial (Part 2).
An "indicated" sample of 120 adolescents in the 7th and 8th grade and their caregivers were randomly assigned to a brief, Individual Support Program (ISP) comparison group or a Skills Group Program.
Research interviews were conducted at multiple timepoints with students and caregivers, and teacher questionnaires were used to examine changes in outcome measures.
Following completion of the intervention, all participants were followed for 12-months.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98115
- Seattle Children's
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 7th and 8th grade students at 4 participating middle schools
- Score 14 or above on the Mood and Feelings Questionnaire at screening (approximately top 25%)
- No imminent plans to move or change to non-participating school
- At minimum 6th grade language skills
- Agree to participate in random assignment and research interviews
- One Parent/caregiver willing to complete research interviews
Exclusion Criteria:
- Student with past or current Major Depressive Disorder (MDD) or Probable MDD
- Students with parents who do not speak English or Spanish
- Students in concurrent treatment
- Students in self-contained classroom, or with cognitive delays, or emotional behavioral problems that would preclude them from benefiting from the group or being a good group member
- Parent not willing to complete research interviews
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Skill Group Program
Positive Thoughts and Actions Program
|
Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students.
The skills group will take place at school during school hours.
Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each).
In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
|
|
Active Comparator: Individual Support Program
Measure of Adolescent Potential for Suicide (MAPS) - modified
|
Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support.
The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school.
Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Moods and Feelings Questionnaire (MFQ; child and parent version)
Time Frame: up to 1 year
|
Depressive symptoms of the child are assessed on the MFQ.
Youth completed the MFQ at all 4 timepoints, parent ratings of students symptoms were collected at baseline, post-intervention, and 12 month follow up.
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parent-Child Communication (PCC; child and parent version)
Time Frame: up to 1 year
|
Parent child communication were assessed using the child and parent version of the PCC.
Children completed the PCC at all 4 timepoints, parent ratings were collected at baseline, post-intervention, and 12 month follow up.
|
up to 1 year
|
|
Behavioral Assessment System for Children-2nd Edition (BASC-2; student, parent, & teacher version)
Time Frame: up to 1 year
|
The adolescent version of the Teacher Rating Scale, Parent Rating Scale, and the Student Self-Report of Personality of the BASC-2 were used to assess school functioning and social functioning.
|
up to 1 year
|
|
Health Enhancing Behavior Index (HEBI)
Time Frame: up to 1 year
|
Health behaviors (diet, exercise, and sleep) are self-reported by the youth on the HEBI.
|
up to 1 year
|
|
Service Use Interview (Service for Children and Adolescence Parent Interview-modified)
Time Frame: up to 1 year
|
The service use interview was used to measure treatment history and services received during the course of the intervention and follow up.
|
up to 1 year
|
|
Schedule for Affective Disorders and Schizophrenia for School-Age Children (KSADS)
Time Frame: up to 1 year
|
The depression module of the KSADS was used to assess DSM-IV symptoms of major depression and depressive disorder at the 12-month follow up.
|
up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Carolyn A McCarty, Ph.D., Seattle Children's Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
October 1, 2012
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
October 5, 2010
First Submitted That Met QC Criteria
October 12, 2010
First Posted (Estimate)
October 14, 2010
Study Record Updates
Last Update Posted (Estimate)
February 14, 2014
Last Update Submitted That Met QC Criteria
February 13, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R34 MH083706
- 5R34MH083076-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on Positive Thoughts and Actions Program
-
York UniversityGovernment of Nunavut; Qaujigiartiit Health Research CentreCompletedDepressive Symptoms | Emotion RegulationCanada
-
Ruhr University of BochumCompletedPsychological Distress | Psychology, PositiveGermany
-
Oregon State UniversityUniversity of Illinois at ChicagoCompletedSubstance Use | Violence | Academic Achievement | Character | Pro-Social BehaviorUnited States
-
Canterbury Christ Church UniversityUniversity of East LondonCompleted
-
BayerOrion Corporation, Orion PharmaCompletedDarolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE)Prostatic NeoplasmsChina, Australia, Taiwan, Latvia, India, Brazil, Canada, Chile, Lithuania, Peru, South Africa, Ukraine, New Zealand, Russia, Spain
-
University of SevilleUniversity of Jaén; Loyola University; Gobierno de CantabriaCompleted
-
Cairo UniversityNot yet recruiting
-
VA Office of Research and DevelopmentCompleted
-
Lucia JimenezNot yet recruiting
-
Centers for Disease Control and PreventionCompletedChild AbuseUnited States